contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


simris-group-ab-announces-positive-results-from-ongoing-antibody-drug-conjugate-adc-study-with-nuvisan

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Simris Group is a biotechnology company. The company is focused on research and development of bioactive substances from cultured microalgae, for applications in nutrition, cosmeceuticals and pharmaceuticals. The company's technology also replaces unsustainable raw materials from endangered species and sensitive marine ecosystems. Simris Group was founded in 2011 and is headquartered in Hammenhög.

Simris Group

Simris Group AB’s wholly owned subsidiary, Simris Biologics GmbH, today announced important progress in its ongoing preclinical study with Nuvisan, a leading European contract research and development...

<div class="mfn-preamble">Simris Group AB’s wholly owned subsidiary, Simris Biologics GmbH, today announced important progress in its ongoing preclinical study with Nuvisan, a leading European contract research and development organization.</div><div class="mfn-body">Three proprietary Microcystin (MC)-based payloads were successfully generated in ADC format and evaluated in in-vitro efficacy studies. In two independent trials, one of the ADC variants demonstrated full-blown toxicity against the corresponding antigen-expressing cancer cell line, indicating complete elimination of cancer cells in response to treatment.This payload candidate, now designated SIMRIS-121, having exhibited excellent potent in-vitro activity, will proceed to the next stage of the Nuvisan study—a dose-escalation in-vivo study to determine the maximum tolerated dose (MTD) of the ADC in mice.<blockquote>“This is a significant milestone for our Microcystin ADC program,” said Dr. Alexis Roberts-McIntosh, CEO of Simris Group AB. “The clear demonstration of full cytotoxicity in one of our MC-ADC candidates confirms the therapeutic potential of our cyanobacterial payload platform. Together with Nuvisan’s deep expertise in preclinical development, we are advancing rapidly toward in-vivo validation.”</blockquote>These results further support Simris’ mission to develop novel, cyanobacteria-derived toxin payloads with improved therapeutic windows and differentiated mechanisms of action for next-generation ADCs.For more information about Simris Biologics, visit: <a rel="noopener" href="https://simrisbiologics.com">https://simrisbiologics.com</a> For more information about Nuvisan, visit: <a rel="noopener" href="https://www.nuvisan.com">https://www.nuvisan.com</a></div><div class="mfn-footer mfn-contacts mfn-b95480a2fa00">Contact Details: Dr Alexis Roberts-McIntosh CEO Simris Group AB Email: <a rel="noopener" href="mailto:ir@simris.com">ir@simris.com</a> Mobile: +44 (0) 7940 585298 www.simrisgroup.com </div><div class="mfn-footer mfn-about mfn-a28d31a3c6e4">About Simris Group AB (PUBL): Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.&nbsp;Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: <a rel="noopener" href="mailto:info@amudova.se">info@amudova.se</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/17b4267f-10f5-49f2-a664-81b2139a8ac8/simris-group-ab-announces-positive-results-from-ongoing-antibody-drug-conjugate-adc-study-with-nuvisan.pdf" class="mfn-generated mfn-primary">Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan</a></div>

Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan